
-
Enanta Pharmaceuticals NasdaqGS:ENTA Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Location: 4 Kingsbury Avenue, Watertown, MA, 02472, United States | Website: https://www.enanta.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
145.7M
Cash
193.4M
Avg Qtr Burn
-13.87M
Short % of Float
20.60%
Insider Ownership
6.57%
Institutional Own.
87.52%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MAVYRET (Glecaprevir) Details HCV (Hepatitis C Virus) | Approved Quarterly sales | |
Zelicapavir (EDP-938) Details Viral infection, Respiratory syncytial virus, Respiratory virus | Phase 2 Data readout | |
EDP-235 Details Viral infection, COVID-19 | Phase 2 Update | |
EDP-514 (HBV Core inhibitor) Details Hepatitis B | Phase 2 Initiation | |
EDP-323 Details Viral infection, Respiratory syncytial virus, Respiratory virus | Phase 2a Update | |
ENP-297 (FXR inhibitor) Details Non-alcoholic steatohepatitis | Failed Discontinued | |
EDP-305 (FXR Agonist) Details Non-alcoholic steatohepatitis | Failed Discontinued |